Background. Localized scleroderma (LSc) is characterized by cutaneous fibrosis and various
INTRODUCTION
Scleroderma, a chronic connective tissue disorder with an autoimmune background, is classified into localized scleroderma (LSc) and systemic sclerosis (SSc). LSc exhibits fibrosis limited to the skin and the subcutaneous tissues beneath the cutaneous lesions, and differs from SSc since LSc is not associated with Raynaud's phenomenon, acrosclerosis, and internal organ involvement [1] . Therefore, the prognosis for LSc patients is fairly good; however, the disfigurement and deformities of the extremities and face resulting from deep fibrosis significantly impair the quality of life [1] . Morphologically, LSc is classified into 3 subsets: morphea, linear scleroderma, and generalized morphea [2] . Morphea is usually characterized by one or a few circumscribed sclerotic plaques with an ivory-colored center and a surrounding violaceous halo. Linear scleroderma appears in a linear, band-like distribution, and often involves the muscle and bone underlying the skin lesions. Generalized morphea is a severe form of LSc characterized by widespread skin involvement with multiple lesions.
LSc exhibits autoimmunity as a central feature of the diseases, since antinuclear antibody (Ab) is detected in 46-80% of patients [3] [4] [5] . These autoantibodies react to various intracellular components, including nucleosome, histone, DNA topoisomerase II, and single-stranded DNA (ssDNA) [3, 4, [6] [7] [8] and also to some enzymes, such as superoxide dismutase (SOD) [9] . In addition, anti-cardiolipin Ab, rheumatoid factor, and lupus erythematosus cell phenomenon have been detected in LSc [4, 10] . However, it remains unknown whether these autoantibodies directly contribute to the disease manifestations of LSc.
Both SSc and LSc show an abnormal accumulation of extracellular matrix (ECM)
components, predominantly types I and III collagens [11] [12] [13] . The net accumulation of ECM in tissue is dependent on the balance between the synthesis and the degradation of ECM 3 components. The latter process is regulated by matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases that collectively can digest all ECM components [14, 15] . MMP-1 (interstitial collagenase-1) is able to initiate degradation of interstitial collagen types I, II, and III [14] . A recent study has shown that autoantibody against MMP-1 is detected in 49% of patients with SSc, especially diffuse cutaneous type of SSc, but not in patients with other autoimmune disorders, such as systemic lupus erythematosus and dermatomyositis [16] . However, it remained unknown whether anti-MMP-1 Ab was also detected in LSc and whether it was related to some clinical manifestations. Therefore, we investigated the presence or levels of anti-MMP-1 Ab, its clinical correlation, and its functional significance in LSc patients.
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MATERIALS AND METHODS
Serum samples
Serum samples were obtained from 41 Japanese patients with LSc (11 males and 30 females).
Patients were classified into the following 3 subgroups as described previously [2] : 12 patients with generalized morphea (2 males and 10 females), 19 patients with linear scleroderma (5 males and 14 females), and 10 patients with morphea (3 males and 7 females). The age of patients with LSc (mean ± SD) was 25.7 ± 17.6 years old (generalized morphea, 22.8 ± 19.8; linear scleroderma, 18.6 ± 10.1; and morphea, 42.0 ± 16.2 years old). The disease duration of patients with LSc was 4.2 ± 5.8 years (generalized morphea, 3.4 ± 2.8; linear scleroderma, 4.8 ± 7.1; and morphea, 4.0 ± 6.3 years). None of LSc patients was treated with oral corticosteroid or other immunosuppressive therapy at the evaluation. The number of sclerotic lesions more than 3 cm in diameter was counted in each patient with LSc when the serum samples were obtained. The sclerotic lesions were morphologically classified into plaque and linear lesions. We divided the whole body into the following 7 areas: head and neck; right upper extremity; left upper extremity; anterior trunk; posterior trunk; right lower extremity; and left lower extremity, then we counted the number of involved areas as described previously [2] . Serum samples from 37
SSc patients who fulfilled the criteria proposed by the American College of Rheumatology [17] were also examined in this study. Thirty-four age-and sex-matched Japanese healthy persons were used as normal controls. Fresh venous blood samples were centrifuged shortly after clot formation. All samples were stored at -70°C prior to use. The protocol was approved by the Kanazawa University Graduate School of Medical Science and Kanazawa University Hospital.
Enzyme-Linked ImmunoSorbent Assay (ELISA) for anti-MMP-1 Ab
ELISA was performed as previously described [16] . Briefly, 96-well plates were coated with human recombinant MMP-1 (1 μg/ml; Techne Corp., Minneapolis, MN, USA) at 4˚C overnight. Detection of antihistone Ab, anti-ssDNA Ab, anti-nucleosome Ab, and rheumatoid factor ELISA for antihistone and anti-ssDNA Ab was performed as described previously [4] . Briefly, 96-well microtiter plates were coated with total histones (5 μg/ml; Sigma-Aldrich Co.) at 4°C overnight. For anti-ssDNA Ab, wells were pretreated with 0.1% protamine sulfate (grade X; Sigma-Aldrich Co.) for 1 hour at 20°C. After rinsing, the plates were coated with calf thymus ssDNA (1 μg/ml; Sigma-Aldrich Co.) at 4°C overnight. ELISA was performed as described for anti-MMP-1 Ab ELISA. Anti-nucleosome Ab was determined by commercial ELISA kits (D-TEK, Mons, Belgium), according to the manufacturer's protocol. Rheumatoid factor was measured using a latex agglutination slide test (Eiken, Tokyo, Japan), according to the manufacture's protocol. 
MMP-1 collagenase activity assay
IgG was purified from serum samples using magnetic beads coated with recombinant Protein G covalently coupled to the surface (Dynal Inc., Lake Success, NY, USA). 
Statistical analysis
Statistical analysis was performed using the Mann-Whitney U test for determining the level of significance of differences between sample means, Fisher's exact probability test for comparison of frequencies, and Bonferroni's test for multiple comparisons. Spearman's rank correlation coefficient was used to examine the relationship between two continuous variables. A p value less than 0.05 was considered statistically significant.
RESULTS
Anti-MMP-1 autoantibody levels by ELISA
The presence and levels of anti-MMP-1 autoantibodies in serum samples from patients with LSc or SSc and normal controls were assessed by ELISA (Figure 1 for IgM anti-MMP-1 Ab) of the control serum samples were considered positive in this study (Figure 1 ). In total patients with LSc, IgG or IgM anti-MMP-1 Ab was found in 46% (Table 1) .
IgG isotype of this autoantibody (39%) was more frequently detected than IgM isotype (10%). 
Immunoblotting analysis for anti-MMP-1 Ab
The presence of anti-MMP-1 Ab was further evaluated by immunoblotting analysis using human 
DISCUSSION
LSc is characterized by skin fibrosis with autoimmune background. Fibroblasts from the affected skin of LSc patients produce increased amount of collagen types I and III and fibronectin [13] [12] , which is also observed in fibroblasts derived from the SSc skin [11] . Furthermore, analysis using fibroblast cultures derived from different layers of the dermis and subcutaneous tissue has shown that the pattern of collagen synthesis in LSc is similar to that of SSc, suggesting that the two diseases have a common pathomechanism [18] . In SSc, a previous study has shown that SSc fibroblasts exhibit decrease in MMP-1 activity and production compared with normal fibroblasts [19] . Likewise, decrease in MMP-1 expression is observed in the LSc fibroblasts [20] . Moreover, the efficacy of ultraviolet A phototherapy on skin fibrosis is mainly obtained by increased production of MMP-1 and interferon-γ in LSc [21] . Collectively, these findings suggest that MMP-1 expression and activity play a role in the development of skin fibrosis in both LSc and Both LSc and SSc exhibit autoimmunity as a central feature of the diseases. SSc exhibits the production of autoantibodies against various intracellular components, such as DNA topoisomerase I, centromere, RNA polymerases, and U3RNP [22] . However, these autoantibodies specific to SSc are absent in LSc with few exceptions [4] . Conversely, autoantibodies against DNA topoisomerase II and SOD, which are detected in LSc, are not found in SSc [8, 9] . Thus, although both SSc and LSc show cutaneous fibrosis, autoantibody specificities associated with these diseases are different. However, LSc and SSc share some autoantibody specificities, such as antihistone Ab, anti-ssDNA Ab, and rheumatoid factor.
Similarly, anti-MMP-1 Ab is detected in both LSc and SSc. Furthermore, anti-MMP-1 Ab is not observed in other autoimmune diseases, including systemic lupus erythematosus and dermatomyositis, suggesting that anti-MMP-1 Ab is specific to LSc and SSc. Therefore, anti-MMP-1 Ab may be an autoantibody closely related to skin fibrosis.
A majority of autoantibodies that have been detected in LSc appear to correlate with the disease severity of LSc: antihistone Ab, anti-ssDNA Ab, and anti-cardiolipin Ab are most frequently positive in generalized morphea, the most severe subset of LSc, compared to linear scleroderma and morphea [4, 10] . Especially, antihistone Ab correlates with total number of lesions and the total area of lesions [2] . On the other hand, autoantibodies against SOD or DNA topoisomerase II are found at comparable frequency between the 3 subgroups of LSc [8, 9] . By contrast, the present study showed that anti-MMP-1 Ab was most frequently detected in morphea (60%), followed by linear scleroderma (47%) and then generalized morphea (25%). The reasons for this phenomenon remained unknown in this study. However, the early diagnosis of morphea is sometime difficult, since early lesions of morphea occasionally show non-specific inflammatory change rather than sclerotic change. Therefore, the presence of anti-MMP-1 Ab would be helpful for diagnosing early stage of morphea. Moreover, LSc patients with anti-MMP-1 Ab exhibited shorter disease duration relative to those without, suggesting that anti-MMP-1 Ab is produced in the early phase of LSc. This finding would also help early detection of morphea.
In SSc, IgG anti-MMP-1 Ab correlates with diffuse cutaneous type of SSc and the extent of skin and lung fibrosis [16] . Furthermore, IgG anti-MMP-1 Ab in sera from SSc patients 13 inhibits MMP-1 collagenase activity [16] , suggesting that IgG anti-MMP-1 Ab contributes to the accumulation of ECM in SSc. Similarly, the current study showed that IgG anti-MMP-1 Ab in sera from LSc patients inhibited MMP-1 collagenase activity. However, the presence of IgG anti-MMP-1 Ab did not correlate with total number of lesions and the total area of lesions in LSc.
Unlike SSc, LSc is characterized by the scattered sclerotic lesions that do not involve the whole body even if the lesions are multiple. Therefore, it remained unknown why systemic production of autoantibodies against MMP-1 in LSc affects only partial body areas, given that the autoantibodies can block collagenase activity of MMP-1. It has been reported that various physical injury, including trauma, radiation, burn, local corticosteroid injection, surgical procedures, immunization, and varicella infection, is a provoking factor in LSc [23, 24] . In addition, MMP-1 expression is induced in response to exogenous signals, such as various cytokines or growth factors, cell-matrix interactions, and cell-cell interactions [14, 15] . Indeed, a recent study has shown that MMP-1 expression is induced during the process of wound healing [25] . Therefore, it may be possible that physical skin injury induces the local expression of (24) 18 (49) Normal ( 
